Nice explanation - dilution is always expected when they have such large trial. Not a bad sign - at least the source of money is locked which will take them to end of trial.
In case there are positive developments on the way, SP will increase and dilution will be lower.
If no good developments, dilution will lead to SP going down below $2.62 and if one wants to wait for 2+ years, they can buy more at lower SP
Thanks for the write up. It all makes sense and lays out the case for why this should not be viewed as a negative.
What remains now is successful trials execution and hopefully results that lead to commercialization, which may still require additional capital through share sales or partnership.
You are correct and your analysis is more readable than what I have tried to express as in my post of a few minutes ago. I agree with you completely. The knee jerk reaction to Friday’s announcement should be ignored. Thank you for your posts.